<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00282672</url>
  </required_header>
  <id_info>
    <org_study_id>B-204</org_study_id>
    <nct_id>NCT00282672</nct_id>
  </id_info>
  <brief_title>Ablation of Intestinal Metaplasia Containing Dysplasia</brief_title>
  <official_title>Ablation of Intestinal Metaplasia Containing Dysplasia (AIM Dysplasia Trial) A Multi-center, Randomized, Sham-Controlled Trial: Protocol Amendment to Extend Follow-up to 5 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic - MITG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the intervention of a 510(k)-cleared
      endoscopically-guided (Halo Ablation systems), ablation system plus anti-secretory therapy is
      better than anti-secretory therapy alone in clearing Barrett's Esophagus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Barrett's esophagus or intestinal metaplasia (IM) is a change in the epithelial lining of the
      esophagus. Barrett's esophagus develops as a result of chronic exposure of the esophagus to
      refluxed stomach acid and enzymes, as well as bile, resulting in recurrent mucosal injury.
      Injury is accompanied by inflammation and, ultimately, a cellular change (metaplasia) to a
      specialized columnar epithelium (Spechler SJ. Barrett's Esophagus. N Engl J Med
      2002;346(11):836-842.)

      Patients who have a diagnosis of Barrett's esophagus typically undergo surveillance endoscopy
      every 1-3 years with multiple biopsy specimens obtained to facilitate early detection of
      progression of IM to dysplasia (more severe precancerous changes) and adenocarcinoma.
      (Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's
      esophagus. Am J Gastro 2002;97:1888-1895.) Progression of IM to low-grade dysplasia (LGD)
      indicates that cells exhibit more &quot;cancer-like&quot; architecture, thus warranting an accelerated
      surveillance endoscopy and biopsy program every 6 months rather than every 1-3 years as
      indicated for non-dysplastic IM. Progression to high-grade dysplasia (HGD) indicates that the
      cells are even more &quot;cancer-like&quot;, thus warranting an even higher frequency surveillance
      endoscopy and biopsy program (every 3 months). Many HGD patients may undergo photodynamic
      therapy (PDT) or surgical esophagectomy, rather than remain in a frequent surveillance
      program. This more aggressive therapy is warranted because of the high rate of progression of
      HGD to adenocarcinoma.

      Esophageal adenocarcinoma most commonly occurs after an insidious progression from IM to LGD
      to HGD. Therefore, surveillance is increased upon diagnosis of worsening grades of dysplasia.
      The incidence of esophageal adenocarcinoma is rapidly increasing as middle-aged and elderly
      demographic sub-groups expand (Peters JH, Hagen JA, DeMeester SR. Barrett's Esophagus. J
      Gastrointest Surg 2004;8(1):1-17.) In 2004, the American Cancer Society reported that there
      were 14,250 new cases of esophageal cancer, and 13,300 deaths attributable to esophageal
      cancer (www.cancer.org). The U.S. National Cancer Institute Surveillance, Epidemiology and
      End Results Program reported that the increasing incidence of esophageal adenocarcinoma was
      greater than for any other cancer in the United States (www.cancer.gov).

      Elimination of the diseased epithelium containing IM with dysplasia is an intuitively
      favorable step for patients with this diagnosis. In other disease states, such as colon
      polyps or premalignant skin lesions, removal of the premalignant tissue results in a
      reduction in the risk of ultimately developing cancer. This is a logical conclusion when
      considering the premalignant lesion of Barrett's esophagus (particularly Barrett's esophagus
      with dysplasia), as the &quot;tissue at risk&quot; can be completely removed by ablation. This premise
      has been tested in the Barrett's dysplasia population in photoablative trials using PDT for
      patients with HGD, where PDT imparted a 50% reduction in risk over controls for the
      development of adenocarcinoma (Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for
      Barrett's esophagus: follow-up. Gastrointest Endosc 1999;49(1):1-7.) The AIM Dysplasia Trial
      primary endpoints are removal of all dysplasia and IM, rather than detection of a difference
      in progression to adenocarcinoma or higher grades of dysplasia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The % of Patients With Complete Eradication of Intestinal Metaplasia (IM) at 12 Month</measure>
    <time_frame>12 month</time_frame>
    <description>% of patients with complete eradication of IM out of the number of participants analyzed at 12 month was calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The % of Patients With Complete Eradication of Dysplasia at 12 Month</measure>
    <time_frame>12 month</time_frame>
    <description>% of patients with complete eradication of Dysplasia out of the number of participants analyzed at 12 month was calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The % of Patients With Complete Histological Clearance of Intestinal Metaplasia at 24 Months.</measure>
    <time_frame>24 Month</time_frame>
    <description>% of patients with complete eradication of IM out of the number of participants analyzed at 24 month was calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>5 Year Extension: % of All Patients Enrolled in the Extension Protocol and Available for Analysis Demonstrating CR-IM at 5 Years</measure>
    <time_frame>5 years</time_frame>
    <description>For patient who made it to the 5 year visit, % of patients demonstrating complete eradication of intestinal metaplasia (CE-IM) was calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Durability of Eradication With no Additional Treatments</measure>
    <time_frame>5 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>5 Year Extension: % of All Patients Enrolled in the Extension Protocol and Available for Analysis Demonstrating CR-D at 5 Years</measure>
    <time_frame>5 years</time_frame>
    <description>For patient who made it to the 5 year visit, % of patients demonstrating complete eradication of dysplasia was calculated and all were free of dysplasia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The % of Patients With Complete Histological Clearance of IM at 12 Months, Comparing Treatment Versus Sham Control Groups Within a Specific Dysplasia Subgroup</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within the HGD Subgroup, the % of Patients With Complete Histological Clearance of HGD (CR-D) at 12 Months, Comparing Treatment Versus Sham Control Groups.</measure>
    <time_frame>12 Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological Clearance of IM (% Biopsies)</measure>
    <time_frame>12 months</time_frame>
    <description>% of patients with histological clearance of IM out of the number of participants analyzed at 12 month was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of Dysplasia (i.e., HGD to Adenocarcinoma, or LGD to HGD or Adenocarcinoma)</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Discomfort : Chest Pain Score on Day 1</measure>
    <time_frame>Day 1 , if ablated</time_frame>
    <description>Chest pain score was measured on a visual analogue scale of 0 to 100, with higher scores indicating a greater severity of pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire (Baseline v. 12 and 24 Mos)</measure>
    <time_frame>0, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Incidence</measure>
    <time_frame>12 months for Treatment and Sham Comparison</time_frame>
    <description>Data reported in the adverse event section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For 5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension and Available for Analysis at 5 Years Demonstrating Any Adenocarcinoma in Any Biopsy Obtained From the Esophageal Body Since Primary RFA (0-5 Years)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension and Available for Analysis at 5 Years Demonstrating Any Adenocarcinoma in Any Biopsy Obtained From the Esophageal Body After 2 Years and Inclusive of the 5 Year Visit</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-IM at 5 Year</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 Year Extension:Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-D at 5 Year</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-IM at 4 Year</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-IM at 3 Year</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-D at 4 Year</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 Year Extension: Serious Adverse Event Incidence</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 Year Extension: All Cause Mortality of the Group From 2 to 5 Years.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Barrett Esophagus</condition>
  <arm_group>
    <arm_group_label>LGD Sham Procedure first then LGD Radiofrequency Ablation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham procedure plus anti-secretory medication. Subjects with Low Grade Dysplasia (LGD) receive proton pump inhibitor (PPI) with dose of Esomeprazole 40 mg BID.
At 12 month, subjects crossover to receive radiofrequency ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LGD:Radiofrequency ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ablation System plus anti-secretory medication. Subjects with Low Grade Dysplasia (LGD) undergo an upper endoscopy with sizing of the esophageal diameter followed by radiofrequency ablation plus standard anti-secretory therapy (proton pump inhibitor, PPI-dose: Esomeprazole 40 mg BID.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HGD Sham Procedure first then HGD Radiofrequency Ablation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham procedure plus anti-secretory medication. Subjects with High Grade Dysplasia (HGD) with proton pump inhibitor (PPI) dose: Esomeprazole 40 mg BID.
At 12 month, subjects crossover to receive radiofrequency ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HGD:Radiofrequency ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ablation System plus anti-secretory medication. Subjects with High Grade Dysplasia (HGD) undergo an upper endoscopy with sizing of the esophageal diameter followed by radiofrequency ablation plus standard anti-secretory therapy (proton pump inhibitor, PPI-dose: Esomeprazole 40 mg BID.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ablation System plus anti-secretory medication</intervention_name>
    <description>Treatment group subjects undergo up to 4 ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI).</description>
    <arm_group_label>LGD:Radiofrequency ablation</arm_group_label>
    <arm_group_label>HGD:Radiofrequency ablation</arm_group_label>
    <other_name>HALO 360</other_name>
    <other_name>HALO 90</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham procedure plus anti-secretory medication</intervention_name>
    <description>The Sham Control group undergo an upper endoscopy procedure with sizing of the esophageal diameter (a component of the ablation procedure steps, deemed the sham procedure) plus standard anti-secretory drug therapy (Proton pump inhibitor, PPI)</description>
    <arm_group_label>LGD Sham Procedure first then LGD Radiofrequency Ablation</arm_group_label>
    <arm_group_label>HGD Sham Procedure first then HGD Radiofrequency Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:1.Subject is 18-80 years of age, inclusive. 2.Subject has documented
        diagnosis of IM, maximum endoscopic length of 8 cm (as measured endoscopically from the TGF
        to the most proximal extent of the IM; i.e. TGF-TIM containing dysplasia as follows:

          1. For LGD:i.LGD documented on biopsy within previous 12 months from enrollment while
             subject on PPI therapy.

             ii.Histology slides reviewed at central pathology service for trial confirm LGD on
             first confirmatory central pathology review or, if necessary, confirm LGD on a
             tie-breaker review by a second pathologist.

          2. For HGD:i.Regular, non-nodular, non-ulcerated mucosa. ii.HGD documented on biopsy
             within previous 6 months from enrollment. iii.Histology slides reviewed at central
             pathology service for Trial confirm HGD on first confirmatory review or, if necessary,
             confirm HGD on a tie-breaker review by a second pathologist.

             iv.Baseline EUS within previous 12 months; 1.Catheter-based EUS excludes suspicious
             thickened Barrett's areas or, if suspicious areas found, prompts stacked biopsies of
             thickened area, the results of which do not render subject ineligible for enrollment.

             3.For subjects with EMR history,the documented diagnosis of IM with dysplasia meets
             criterion #2 from biopsies collected either after the EMR procedure or during the EMR
             procedure but not from the EMR site.

             4.Subject able to take oral proton pump inhibitor medication. 5.Subject able to
             discontinue aspirin and/or non-steroidal anti-inflammatory medications 7 days before
             and after all ablation procedures.

             6.For female subjects of childbearing potential, a negative pregnancy test within 2
             weeks of randomization.

             7.Subject eligible for treatment and follow-up endoscopy and biopsy as required by the
             Protocol.

             8.Subject willing to provide written, informed consent to participate in this clinical
             study and understands the responsibilities of trial participation.

             Exclusion Criteria:1.The subject is pregnant or planning a pregnancy during the study
             period.

             2.Esophageal stricture preventing passage of endoscope or catheter. 3.Active
             esophagitis described as erosions or ulcerations encompassing more than 10% of distal
             esophagus.

             4.Any history of malignancy of the esophagus. 5.Prior radiation therapy to the
             esophagus,except head and neck region radiation therapy.

             6.Any previous ablative therapy within the esophagus (PDT, MPEC, APC, laser treatment,
             other).

             7.History of EMR that meets any of the following criteria:a.EMR performed less than 8
             weeks prior to the randomization endoscopy encounter

        b.EMR performed in a wide field manner (encompassing more than 90 degrees of any area of
        the esophagus.

        8.Any previous esophageal surgery, including except fundoplication without complications
        (i.e. no slippage, dysphagia, etc).

        9.Evidence of esophageal varices during treatment endoscopy. 10.Report of uncontrolled
        coagulopathy with international normalized ratio (INR) &gt; 1.3 or platelet count &lt;75,000
        platelets per ÂµL 11.Subject has a life-expectancy of less than two years due to an
        underlying medical condition.

        12.Subject has a known history of unresolved drug or alcohol dependency that would limit
        ability to comprehend or follow instructions related to informed consent, post-treatment
        instructions, or follow-up guidelines.

        13.Subject has an implantable pacing device (examples; AICD, neurostimulator, cardiac
        pacemaker)and has not received clearance for enrollment in this study by specialist
        responsible for the pacing device.

        14.The subject is currently enrolled in an investigational drug or device trial that
        clinically interferes with the AIM Dysplasia Trial endpoints.

        15.Subject suffers from psychiatric or other illness deemed by the investigator as an
        inability to comply with protocol.

        For the 5 year extension, patient must have:1. Enrolled in the B-204 protocol. 2. Completed
        1 year follow-up. 3. Completed 2 year follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas J Shaheen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona, VAMC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard, VA Boston Healthcare W Roxbury</name>
      <address>
        <city>West Roxbury</city>
        <state>Massachusetts</state>
        <zip>02132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas School of Medicine - Veterans Affairs Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Center for Functional GI &amp; Motility Disorders</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Associates</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VAMC Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tacoma Digestive Disease Research Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dunkin BJ, Martinez J, Bejarano PA, Smith CD, Chang K, Livingstone AS, Melvin WS. Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon device. Surg Endosc. 2006 Jan;20(1):125-30. Epub 2005 Dec 7.</citation>
    <PMID>16333533</PMID>
  </reference>
  <reference>
    <citation>Ganz RA, Utley DS, Stern RA, Jackson J, Batts KP, Termin P. Complete ablation of esophageal epithelium with a balloon-based bipolar electrode: a phased evaluation in the porcine and in the human esophagus. Gastrointest Endosc. 2004 Dec;60(6):1002-10.</citation>
    <PMID>15605025</PMID>
  </reference>
  <results_reference>
    <citation>Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, Galanko JA, Bronner MP, Goldblum JR, Bennett AE, Jobe BA, Eisen GM, Fennerty MB, Hunter JG, Fleischer DE, Sharma VK, Hawes RH, Hoffman BJ, Rothstein RI, Gordon SR, Mashimo H, Chang KJ, Muthusamy VR, Edmundowicz SA, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Falk GW, Kimmey MB, Madanick RD, Chak A, Lightdale CJ. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009 May 28;360(22):2277-88. doi: 10.1056/NEJMoa0808145.</citation>
    <PMID>19474425</PMID>
  </results_reference>
  <results_reference>
    <citation>Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK, Fleischer DE, Sharma VK, Eisen GM, Fennerty MB, Hunter JG, Bronner MP, Goldblum JR, Bennett AE, Mashimo H, Rothstein RI, Gordon SR, Edmundowicz SA, Madanick RD, Peery AF, Muthusamy VR, Chang KJ, Kimmey MB, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Dumot JA, Falk GW, Galanko JA, Jobe BA, Hawes RH, Hoffman BJ, Sharma P, Chak A, Lightdale CJ. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology. 2011 Aug;141(2):460-8. doi: 10.1053/j.gastro.2011.04.061. Epub 2011 May 6.</citation>
    <PMID>21679712</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2006</study_first_submitted>
  <study_first_submitted_qc>January 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <results_first_submitted>September 11, 2015</results_first_submitted>
  <results_first_submitted_qc>December 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2015</results_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Barrett's Esophagus</keyword>
  <keyword>Dysplasia</keyword>
  <keyword>Radiofrequency Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
    <mesh_term>Metaplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LGD Sham Procedure First Then LGD Radiofrequency Ablation</title>
          <description>After the 1 year follow up was completed, all sham patients were offered cross-over to receive RFA.</description>
        </group>
        <group group_id="P2">
          <title>LGD Radiofrequency Ablation</title>
        </group>
        <group group_id="P3">
          <title>HGD Sham Procedure First Then HGD Radiofrequency Ablation</title>
          <description>After the 1 year follow up was completed, all sham patients were offered cross-over to receive RFA.</description>
        </group>
        <group group_id="P4">
          <title>HGD Radiofrequency Ablation</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>1 Year</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>2 Year: Sham Crossed Over to RFA</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19">19 crossed over to RFA treatment</participants>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="16">16 Crossed over to RFA treatment</participants>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>5 Year: Follow up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15">1 withdrew</participants>
                <participants group_id="P2" count="32">7 withdrew</participants>
                <participants group_id="P3" count="12">3 withdrew</participants>
                <participants group_id="P4" count="25">11 withdrew</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LGD Sham Procedure First Then LGD Radiofrequency Ablation</title>
          <description>After the 1 year follow up was completed, all sham patients were offered cross-over to receive RFA.</description>
        </group>
        <group group_id="B2">
          <title>LGD Radiofrequency Ablation</title>
        </group>
        <group group_id="B3">
          <title>HGD Sham Procedure First Then LGD Radiofrequency Ablation</title>
          <description>After the 1 year follow up was completed, all sham patients were offered cross-over to receive RFA.</description>
        </group>
        <group group_id="B4">
          <title>HGD Radiofrequency Ablation</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="42"/>
            <count group_id="B5" value="127"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="1.9"/>
                    <measurement group_id="B2" value="66.3" spread="1.4"/>
                    <measurement group_id="B3" value="67.3" spread="1.8"/>
                    <measurement group_id="B4" value="65.9" spread="1.4"/>
                    <measurement group_id="B5" value="65.95" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The % of Patients With Complete Eradication of Intestinal Metaplasia (IM) at 12 Month</title>
        <description>% of patients with complete eradication of IM out of the number of participants analyzed at 12 month was calculated.</description>
        <time_frame>12 month</time_frame>
        <population>LGD: Radiofrequency group- 2 patients withdrew and were not analyzed, HGD: Radiofrequency Ablation: 4 patients withdrew and were not analyzed. LGD Sham procedure first then LGD Radiofrequency Ablation group and HGD Sham procedure first then HGD Radiofrequency Ablation group were not analyzed to measure the CR-IM at one year.</population>
        <group_list>
          <group group_id="O1">
            <title>LGD:Radiofrequency Ablation</title>
          </group>
          <group group_id="O2">
            <title>HGD:Radiofrequency Ablation</title>
          </group>
        </group_list>
        <measure>
          <title>The % of Patients With Complete Eradication of Intestinal Metaplasia (IM) at 12 Month</title>
          <description>% of patients with complete eradication of IM out of the number of participants analyzed at 12 month was calculated.</description>
          <population>LGD: Radiofrequency group- 2 patients withdrew and were not analyzed, HGD: Radiofrequency Ablation: 4 patients withdrew and were not analyzed. LGD Sham procedure first then LGD Radiofrequency Ablation group and HGD Sham procedure first then HGD Radiofrequency Ablation group were not analyzed to measure the CR-IM at one year.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The % of Patients With Complete Eradication of Dysplasia at 12 Month</title>
        <description>% of patients with complete eradication of Dysplasia out of the number of participants analyzed at 12 month was calculated.</description>
        <time_frame>12 month</time_frame>
        <population>LGD: Radiofrequency group- 2 patients withdrew and were not analyzed, HGD: Radiofrequency Ablation: 4 patients withdrew and were not analyzed. LGD Sham procedure first then LGD Radiofrequency Ablation group and HGD Sham procedure first then HGD Radiofrequency Ablation group were not analyzed to measure the CR-D at one year.</population>
        <group_list>
          <group group_id="O1">
            <title>LGD:Radiofrequency</title>
          </group>
          <group group_id="O2">
            <title>HGD:Radiofrequency</title>
          </group>
        </group_list>
        <measure>
          <title>The % of Patients With Complete Eradication of Dysplasia at 12 Month</title>
          <description>% of patients with complete eradication of Dysplasia out of the number of participants analyzed at 12 month was calculated.</description>
          <population>LGD: Radiofrequency group- 2 patients withdrew and were not analyzed, HGD: Radiofrequency Ablation: 4 patients withdrew and were not analyzed. LGD Sham procedure first then LGD Radiofrequency Ablation group and HGD Sham procedure first then HGD Radiofrequency Ablation group were not analyzed to measure the CR-D at one year.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The % of Patients With Complete Histological Clearance of Intestinal Metaplasia at 24 Months.</title>
        <description>% of patients with complete eradication of IM out of the number of participants analyzed at 24 month was calculated.</description>
        <time_frame>24 Month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LGD Sham Procedure First Then LGD Radiofrequency Ablation</title>
            <description>Crossed over to LGD:Radiofrequency</description>
          </group>
          <group group_id="O2">
            <title>LGD:Radiofrequency</title>
          </group>
          <group group_id="O3">
            <title>HGD Sham Procedure First Then HGD Radiofrequency Ablation</title>
            <description>Crossed over to HGD: Radiofrequency</description>
          </group>
          <group group_id="O4">
            <title>HGD Radiofrequency Ablation</title>
          </group>
        </group_list>
        <measure>
          <title>The % of Patients With Complete Histological Clearance of Intestinal Metaplasia at 24 Months.</title>
          <description>% of patients with complete eradication of IM out of the number of participants analyzed at 24 month was calculated.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="97.4"/>
                    <measurement group_id="O3" value="93.3"/>
                    <measurement group_id="O4" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>5 Year Extension: % of All Patients Enrolled in the Extension Protocol and Available for Analysis Demonstrating CR-IM at 5 Years</title>
        <description>For patient who made it to the 5 year visit, % of patients demonstrating complete eradication of intestinal metaplasia (CE-IM) was calculated.</description>
        <time_frame>5 years</time_frame>
        <population>patient who made it to the 5 year visit</population>
        <group_list>
          <group group_id="O1">
            <title>All LGD Patients</title>
            <description>LGD: Sham procedure group crossed over to LGD: Radiofrequency group at 12 month</description>
          </group>
          <group group_id="O2">
            <title>All HGD Patients</title>
            <description>HGD: Sham procedure group crossed over to HGD: Radiofrequency group at 12 month</description>
          </group>
        </group_list>
        <measure>
          <title>5 Year Extension: % of All Patients Enrolled in the Extension Protocol and Available for Analysis Demonstrating CR-IM at 5 Years</title>
          <description>For patient who made it to the 5 year visit, % of patients demonstrating complete eradication of intestinal metaplasia (CE-IM) was calculated.</description>
          <population>patient who made it to the 5 year visit</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3"/>
                    <measurement group_id="O2" value="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Durability of Eradication With no Additional Treatments</title>
        <time_frame>5 year</time_frame>
        <population>41 LGD subjects and 32 HGD subjects completed 5 year visit</population>
        <group_list>
          <group group_id="O1">
            <title>All Groups</title>
          </group>
        </group_list>
        <measure>
          <title>Durability of Eradication With no Additional Treatments</title>
          <population>41 LGD subjects and 32 HGD subjects completed 5 year visit</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>5 Year Extension: % of All Patients Enrolled in the Extension Protocol and Available for Analysis Demonstrating CR-D at 5 Years</title>
        <description>For patient who made it to the 5 year visit, % of patients demonstrating complete eradication of dysplasia was calculated and all were free of dysplasia</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All LGD Patients</title>
          </group>
          <group group_id="O2">
            <title>All HGD Patients</title>
          </group>
        </group_list>
        <measure>
          <title>5 Year Extension: % of All Patients Enrolled in the Extension Protocol and Available for Analysis Demonstrating CR-D at 5 Years</title>
          <description>For patient who made it to the 5 year visit, % of patients demonstrating complete eradication of dysplasia was calculated and all were free of dysplasia</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The % of Patients With Complete Histological Clearance of IM at 12 Months, Comparing Treatment Versus Sham Control Groups Within a Specific Dysplasia Subgroup</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LGD Radiofrequency Ablation</title>
          </group>
          <group group_id="O2">
            <title>LGD Sham Procedure First Then LGD Radiofrequency Ablation</title>
          </group>
          <group group_id="O3">
            <title>HGD Radiofrequency Ablation</title>
          </group>
          <group group_id="O4">
            <title>HGD Sham Procedure First Then HGD Radiofrequency Ablation</title>
          </group>
        </group_list>
        <measure>
          <title>The % of Patients With Complete Histological Clearance of IM at 12 Months, Comparing Treatment Versus Sham Control Groups Within a Specific Dysplasia Subgroup</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="72.2"/>
                    <measurement group_id="O3" value="81.5"/>
                    <measurement group_id="O4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within the HGD Subgroup, the % of Patients With Complete Histological Clearance of HGD (CR-D) at 12 Months, Comparing Treatment Versus Sham Control Groups.</title>
        <time_frame>12 Month</time_frame>
        <population>16 HGD Sham procedure subjects crossed over to RFA treatment after one year</population>
        <group_list>
          <group group_id="O1">
            <title>HGD Radiofrequency Ablation</title>
          </group>
          <group group_id="O2">
            <title>HGD Sham Procedure First Then HGD Radiofrequency Ablation</title>
          </group>
        </group_list>
        <measure>
          <title>Within the HGD Subgroup, the % of Patients With Complete Histological Clearance of HGD (CR-D) at 12 Months, Comparing Treatment Versus Sham Control Groups.</title>
          <population>16 HGD Sham procedure subjects crossed over to RFA treatment after one year</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.4"/>
                    <measurement group_id="O2" value="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Histological Clearance of IM (% Biopsies)</title>
        <description>% of patients with histological clearance of IM out of the number of participants analyzed at 12 month was calculated.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LGD Radiofrequency Ablation</title>
          </group>
          <group group_id="O2">
            <title>LGD Sham Procedure First Then LGD Radiofrequency Ablation</title>
          </group>
          <group group_id="O3">
            <title>HGD Radiofrequency Ablation</title>
          </group>
          <group group_id="O4">
            <title>HGD Sham Procedure First Then HGD Radiofrequency Ablation</title>
          </group>
        </group_list>
        <measure>
          <title>Histological Clearance of IM (% Biopsies)</title>
          <description>% of patients with histological clearance of IM out of the number of participants analyzed at 12 month was calculated.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="72.2"/>
                    <measurement group_id="O3" value="81.5"/>
                    <measurement group_id="O4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression of Dysplasia (i.e., HGD to Adenocarcinoma, or LGD to HGD or Adenocarcinoma)</title>
        <time_frame>5 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LGD to HGD</title>
          </group>
          <group group_id="O2">
            <title>LGD to IMC</title>
          </group>
          <group group_id="O3">
            <title>HGD to IMC</title>
          </group>
        </group_list>
        <measure>
          <title>Progression of Dysplasia (i.e., HGD to Adenocarcinoma, or LGD to HGD or Adenocarcinoma)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Discomfort : Chest Pain Score on Day 1</title>
        <description>Chest pain score was measured on a visual analogue scale of 0 to 100, with higher scores indicating a greater severity of pain</description>
        <time_frame>Day 1 , if ablated</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LGD Sham Procedure First Then LGD Radiofrequency Ablation</title>
          </group>
          <group group_id="O2">
            <title>LGD Radiofrequency Ablation</title>
          </group>
          <group group_id="O3">
            <title>HGD Sham Procedure First Then HGD Radiofrequency Ablation</title>
          </group>
          <group group_id="O4">
            <title>HGD Radiofrequency Ablation</title>
          </group>
        </group_list>
        <measure>
          <title>Subject Discomfort : Chest Pain Score on Day 1</title>
          <description>Chest pain score was measured on a visual analogue scale of 0 to 100, with higher scores indicating a greater severity of pain</description>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="26" lower_limit="4" upper_limit="48"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="22" lower_limit="0" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Questionnaire (Baseline v. 12 and 24 Mos)</title>
        <time_frame>0, 12, and 24 months</time_frame>
        <population>Data had not been collected consistently to analyze the data.</population>
        <group_list>
          <group group_id="O1">
            <title>All Groups</title>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Questionnaire (Baseline v. 12 and 24 Mos)</title>
          <population>Data had not been collected consistently to analyze the data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event Incidence</title>
        <description>Data reported in the adverse event section</description>
        <time_frame>12 months for Treatment and Sham Comparison</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham Patients</title>
            <description>Patients randomized to Sham Procedure arm.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Patients</title>
            <description>Patients randomized to Radiofrequency Ablation at start of study and underwent RFA treatment at randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event Incidence</title>
          <description>Data reported in the adverse event section</description>
          <units>Adverse event occurrences</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE's related to procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE's unrelated to procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>For 5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension and Available for Analysis at 5 Years Demonstrating Any Adenocarcinoma in Any Biopsy Obtained From the Esophageal Body Since Primary RFA (0-5 Years)</title>
        <time_frame>5 years</time_frame>
        <population>41 LGD patients and 21 HGD subjects completed the 5 year study and used for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>All Groups</title>
          </group>
        </group_list>
        <measure>
          <title>For 5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension and Available for Analysis at 5 Years Demonstrating Any Adenocarcinoma in Any Biopsy Obtained From the Esophageal Body Since Primary RFA (0-5 Years)</title>
          <population>41 LGD patients and 21 HGD subjects completed the 5 year study and used for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension and Available for Analysis at 5 Years Demonstrating Any Adenocarcinoma in Any Biopsy Obtained From the Esophageal Body After 2 Years and Inclusive of the 5 Year Visit</title>
        <time_frame>5 years</time_frame>
        <population>Similar analysis was performed and the result is provided for the outcome measure #14. The data were collected to answer the outcome measure #14.</population>
        <group_list>
          <group group_id="O1">
            <title>All Groups</title>
          </group>
        </group_list>
        <measure>
          <title>5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension and Available for Analysis at 5 Years Demonstrating Any Adenocarcinoma in Any Biopsy Obtained From the Esophageal Body After 2 Years and Inclusive of the 5 Year Visit</title>
          <population>Similar analysis was performed and the result is provided for the outcome measure #14. The data were collected to answer the outcome measure #14.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-IM at 5 Year</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Groups</title>
          </group>
        </group_list>
        <measure>
          <title>5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-IM at 5 Year</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5 Year Extension:Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-D at 5 Year</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Groups</title>
          </group>
        </group_list>
        <measure>
          <title>5 Year Extension:Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-D at 5 Year</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-IM at 4 Year</title>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Groups</title>
          </group>
        </group_list>
        <measure>
          <title>5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-IM at 4 Year</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-IM at 3 Year</title>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Groups</title>
          </group>
        </group_list>
        <measure>
          <title>5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-IM at 3 Year</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-D at 4 Year</title>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Groups</title>
          </group>
        </group_list>
        <measure>
          <title>5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-D at 4 Year</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5 Year Extension: Serious Adverse Event Incidence</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
          </group>
        </group_list>
        <measure>
          <title>5 Year Extension: Serious Adverse Event Incidence</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bleed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5 Year Extension: All Cause Mortality of the Group From 2 to 5 Years.</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Groups</title>
          </group>
        </group_list>
        <measure>
          <title>5 Year Extension: All Cause Mortality of the Group From 2 to 5 Years.</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LGD Sham Procedure First Then LGD Radiofrequency Ablation</title>
        </group>
        <group group_id="E2">
          <title>LGD Radiofrequency Ablation</title>
        </group>
        <group group_id="E3">
          <title>HGD Sham Procedure First Then HGD Radiofrequency Ablation</title>
        </group>
        <group group_id="E4">
          <title>HGD Radiofrequency Ablation</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>PAIN, NAUSEA, VOMITTING, FULLNESS, ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Upper GI Bleed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>MUCOSAL INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>MELENA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>STRICTURE REQUIRING DILATATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>VOMITTING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CHEST PAIN/ THROAT PAIN / NAUSEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>STRICTURE / SCARRING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>BLOATED, REFLUX SENSATION, DIFFICULTY SWALLOWING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>NARROWED ESOPHAGUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ESOPHAGEAL VARICES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>FEVER; DIARRHEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PAINFUL SWALLOWING / CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PREMATURE FULLNESS WITH MEALS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PAINFUL SWALLOWING, ABDOMINAL PAIN, CHEST PAIN.</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>FEVER, LARYNGITIS, PHARYNGITIS AND BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SEVERE NAUSEA,VOMITING, ULCERATION, WEIGHT LOSS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ULCERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>EROSIVE ESOPHAGEAL MUCOSA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>RIGHT EAR ACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PAIN; ELEVATED BP</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nicholas Shaheen</name_or_title>
      <organization>University of north Carolina</organization>
      <phone>(919) 966-7047</phone>
      <email>nshaheen@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

